European Journal of Cancer

Article	Citations
The impossibility of mortality evaluation of skin cancer screening in Germany based on health insurance data: a case–control study	349
Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome	184
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONA	172
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life	155
Onco-functional outcome after resection for eloquent glioblastoma (OFO): A propensity-score matched analysis of an international, multicentre, cohort study	154
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm,	152
Gut microbiome and immune checkpoint inhibitor toxicity	149
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database	131
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast	128
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ	125
Editorial Board	121
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial	116
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study	116
“Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools	112
A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer	108
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice	107
The development of an archive of patient-reported outcome measures (PROMs) in oncology: The Italian PRO4All project	106
Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data	102
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomize	92
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial	91
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC	91
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy	86
Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer	86
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer	85
New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown	84

Shining a LIGHT on myeloid cell targeted immunotherapy	83
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis	79
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis	75
Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer – A national cohort study	75
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy	74
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy	73
Precision medicine for KRAS wild-type pancreatic adenocarcinomas	71
Troponin increase during immunotherapy: Not always myocarditis	69
Cancer and immunotherapy: a role for microbiota composition	69
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies	69
Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis	67
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands	67
Gene expression-based prediction of pazopanib efficacy in sarcoma	65
Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis	62
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes	62
CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer	60
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer	59
The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer	59
Artificial intelligence-assisted probability scoring for differentiation of early mycosis fungoides and benign inflammatory dermatoses on H&E stained pathology slides of skin biopsies	57
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inh	56
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma	56
Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study	56
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort	56
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial	56
10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis	56
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy	55
Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study	55
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma	53
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy	53
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)	53
Kidney function assessment for eligibility in clinical cancer trials – Data from the European Organisation for Research and Treatment of Cancer	52
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability	52
Editorial Board	51
Letter Re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma	50
Long-term exposure to air pollution at residential and workplace addresses and breast cancer risk: A case-control study nested in the French E3N-Générations cohort from 1990 to 2011	49
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting	49
PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors	49
Early versus late response to PD-1-based immunotherapy in metastatic melanoma	48
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 tr	48
Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials	47
Editorial Board	47
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer	47
Can we recommend surgical treatment to the octogenarian with periampullary cancer?: National database analysis in South Korea	46
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische O	46
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial	46
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB	45
Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing	44
Editorial Board	44
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants	44
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression	44

Prospectively shared control data across concurrent randomised clinical trials	44
Sonographic assessment of the axilla in breast cancer: changing the threshold	43
Triple negative breast cancers: Rising menace in the developing world and treatment challenges	43
False-Negative Rates Between Pathological Lymph Node Status Between Ductal and Lobular Breast Cancer: A Retrospective Cohort Study of 83,152 Patients	43
A retrospective evaluation of factors associated with upstage to malignancy for breast lesions of uncertain malignant potential (B3): findings from an American cohort	43
Spatial Immunophenotyping Identifies Differential Infiltration of Immunosuppressive Subsets in Tumor Stroma and Invasive Margin and PDL1 expression in Inflammatory and non-Inflammatory Breast Cancer P	43
Alectinib induced vitiligo with rapid re-pigmentation	43
PAM50 genomic test in the management of early breast cancer – the importance of clinical-pathological data	43
Surgical choices and complications in elderly women: a single center retrospective analysis in frail vs non frail breast cancer patients	43
Author Index	42
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)	42
Local recurrence of breast cancer after mastectomy. Impact of residual tissue in cancer follow-up	42
Adding metabolic agents to prostate cancer therapy: Every rose has its thorn	42
Impact of orthotopic versus subcutaneous implantation on patient-derived xenograft transcriptomic profile	41
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults	41
First-in-class heterobifunctional proteomimetic polymer capable of direct inhibition of Myc and target it for degradation	41
STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T cell subset	41
NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma	41
Cutaneous manifestation of mature plasmacytoid dendritic cell proliferation in patients with myeloid leukemia	41
CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors	41
Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer	41
SNP rs10748643 within the promoter region of ENTPD1 (the gene encoding CD39) has no prognostic value in Sézary patients	40
A novel dual PARP-HDAC inhibitor for treatment of Ewing sarcoma	40
Advances in the development of a targeted N-Terminal Domain androgen receptor (AR) degrader (ANITAC) for the treatment of prostate cancer	40
Covalent pan-TEAD inhibitors for the treatment of cancers with Hippo pathway alterations	40
Cutaneous relapses location in diffuse large B-cell lymphoma leg type after immunochemotherapy	40
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition	40
KRASG12C Inhibitor, VRTX126 in combination with Tyrosine Kinase Inhibitor, leads to pronounced and effective response in G12C-mutated cancers	40
Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative brea	40
T cell receptor beta constant 1 as a potential marker to better assess T cell clonality in skin samples	39
Single-cell RNA sequencing characterization of primary cutaneous B-cell lymphomas with their systemic counterparts	39
CCR8 expression as a potential diagnostic and therapeutic biomarker in cutaneous T-cell lymphoma	39
ERK3/MAPK6 has a dual role as pro-and anti-tumorigenic in Triple-Negative Breast Cancer	38
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	38
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	38
Combination Therapy with Poly-gamma-glutamic Acid and Anti-PD-1 Results in Synergistic Therapeutic Effects against Cancers	38
CD8 positive Sézary syndrome: two cases	38
NUC-3373 induces DAMPs release from NSCLC cells potentiating a favourable immunogenic microenvironment	37
Omomyc downregulates MYC transcriptional signature in preclinical models of solid tumours and shows long half-life in tumour tissue	37
The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds	37
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	37
Ultrasound-induced cavitation enhances therapeutic efficacy of AXL-targeting ADC leading to improved survival in a human xenograft model of renal cancer	36
Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V	36
High-Throughput Screening Identifies Novel ROS-Inducing Small Molecules as a Therapy for Treatment-Resistant Melanoma	36
HR-LiP, a novel structural proteomics approach for the prediction of small molecule drug-protein binding events	36
Molecular crosstalk between NF-κB and NRF2 signaling affects prognosis in HPV-associated head and neck cancer	36
The anti-CD205 antibody drug conjugate MEN1309/OBT076 shows synergistic activity in combination with the monoclonal antibody rituximab in diffuse large B cell lymphomas	36
Treatment strategies based on the molecular subtypes of transformed small cell lung cancer (t-SCLC)	36
Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors	35
Targeting the exosome biogenesis pathway to overcome daratumumab resistance in hematological cancers	35
Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma	35
Cellular hormone metabolism is critical for canonical androgen receptor antagonist activity	34
Low SKP2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML	34
Axitinib-related cardiac dysfunction occurring after resumption of treatment	34
Epithelial-Mesenchymal plasticity mediates acquired resistance to eribulin in breast cancer	34
Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”	34
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations	34
Design and development of an innovative, safe, and highly potent E1 ubiquitin-activating enzyme inhibitor CPL–410-005 conjugate in anticancer therapy	33
Testing alternative schedules of adjuvant immune checkpoint blockers – The need for well-designed clinical trials	33
Preliminary results from HERKULES-1: a phase 1b/2, open-label, multicenter study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors	33
Discovery of Essential microRNA in Prostate Cancer Cells	33
Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities	33
Differentiating lymphocytic hypereosinophilic syndrome from Sézary syndrome using transcriptomic analysis	32
A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma	32
Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit	32
HORMAD1 drives spindle assembly checkpoint defects and sensitivity to multiple mitotic kinases	32
New drugs and options can enhance patient outcomes: But can they also erode them?	32
Neutralizing antibody for S100A8/A9 soil sensing signal to prevent metastatic disease	32
Updated Findings and Biomarker Analysis From the Ongoing Phase 1 Study of Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors	32
Pancreatic cancer models exhibit interferon-independent resistance mechanisms to a Morreton hybrid oncolytic vesiculovirus	32
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	32
Developing a preclinical CD47 IHC assay using patient-like samples for the development of a companion diagnostic for CD47-targeting treatments	32
Re-treatment approaches in patients with cutaneous-T-cell lymphoma: a real-life experience	31
Activity and safety of ipatasertib (ipat) for AKT activating mutation and/ or PTEN loss/loss of function solid tumors from MyTACTIC	31
DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a	31
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition	31
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies	30
Combination of JAKi and HDACi as a potential anti-angiogenic treatment in a cutaneous T-cell lymphoma (CTCL) in vivo chick embryo model	30
Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome	30
Real-world effectiveness of mogamulizumab in patients with Sézary syndrome or mycosis fungoides in Spain and Portugal: The MIBERIC study	30

A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients tre	30
rOPCML-Fc as a potential tumor suppressive therapeutic agent for ovarian cancer	30
Ornithine decarboxylase as a new target for improving the effect of KRAS-G12C inhibitors in non-small cell lung cancer cells	30
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	30
Copyright Page	29
Polyamine transport inhibition with AMXT-1501 synergizes with cisplatin in HNSCC	29
The combination of the metabolism-based targeted therapies ADI-PEG20 and GC7 are a promising strategy for the treatment of malignant pleural mesothelioma	29
Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile	29
A novel anti-cancer compound development targeting YAP-TEAD protein-protein interaction	29
The value of digital PCR-based quantification of DNA methylation biomarkers in diagnostic challenging early Sézary syndrome patients	29
Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges	29
Interactions between BRD4 short, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer	29
Transcriptome and computational analysis assess the anti-tubulin activity of [1,2]oxazole derivatives in lymphoma	29
Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53	29
Transcriptomic profiling to identify key players of Ewing Sarcoma metastasis	29
Non-invasive digital disease severity scoring compared to CAILS in early-stage mycosis fungoides	29
Anticancer activity of (±)-kusunokinin derivatives as a new HSP90 inhibitor	29
Table of Contents	29
Capmatinib response in patients with advanced non–small cell lung cancer (NSCLC) harboring focal MET amplifications: Analysis from the phase 2, multicohort GEOMETRY mono-1 study	29
A Ph-Ib study of TRK-950 combined with anti-cancer treatment regimens in patients with advanced solid tumors	28
CAR-T cell engineering strategies aimed at safe and effective targeting of solid tumors	28
The novel, telomerase-directed, telomere-targeted, anticancer agent 6-thio-dG (THIO) demonstrates potent activity and induces antitumor immunity in hepatocellular carcinoma (HCC) models	28
Response of Human and Canine Tumor Cell Lines to Pharmacologic and Genetic Autophagy Inhibition	28
NP-G2-044, a First-in-Class Fascin Inhibitor, Inhibits Growth and Metastasis of Gynecologic Cancers	28
Ex vivo harmonic generation microscopy assessment in cutaneous T-cell lymphomas diagnosis	28
The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib	28
Re: A transcriptomic signature that predicts cancer recurrence following hepatectomy in patients with colorectal liver metastases	27
Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies	27
Non-clinical identification and characterization of KRAS G12D inhibitors	27
Response to letter entitled: Re: ‘Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial’	27
Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration, restricts the development and metastasis of solid malignancies and improves their response to immunotherapy	27
Establishment and characterization of HPV+ metastatic squamous cell anal carcinoma XPDX models in athymic nude mice	27
PIN-A1, a novel Casein Kinase 1α-selective molecular glue degrader, demonstrates strong antitumor activity via activation of the p53 pathway in preclinical models of AML with a favorable safety profil	27
6-gingerol Suppresses Angiogenesis and Promotes T-cell cytotoxicity in Mice Model of Colorectal Cancer	27
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study)	27
Letter re: “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis”	26
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma	26
Re: A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases	26
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours	26
Response to comment on “Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer”	26
Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctD	26
Regression of intestinal diffuse large B cell lymphoma after treatment with vedolizumab in a patient with Crohn's disease	26
A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases	26
Letter Re: Survival trends in solid cancers in the Nordic countries through 50 years	26
Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia—results of a double-blind, randomised controlled trial with cross-over de	26
Response to letter Re: Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies	26
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view	25
Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy	25
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial	25
Shared decision-making in breast cancer care: Evidence from a scoping literature review and a survey across breast units in Europe	25
The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review	25
Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma	25
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data	25
Retrospective thorough analysis of regional lymph node recurrence in breast cancer patients (REASON Trial)	25
Unusual ocular manifestations of breast carcinoma: A single institute case series in the Indian population	25
Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: a survey within the MINDACT cohort	25
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases	25
Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population	25
Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!	25
Advanced breast cancer journey: a consensus guidance from a multidisciplinary panel for improving clinical practice in Portugal	25
Factors affecting Quality of Life among breast cancer survivors	25
Predictive factors of macrometastasis in sentinel lymph node in invasive lobular carcinoma	24
Margin status and Survival outcomes following breast conservation surgery: a metaanalysis	24
Anxiety and depression screening during neoadjuvant chemotherapy treatment in early breast cancer patients: a multicenter longitudinal observational study	24
Re: Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy	24
Preoperative MRI in women with newly diagnosed breast cancer: re-excision rates and additional findings	24
Myalgias upon PD-1 checkpoint blockade: Think of immunotherapy induced hypothyroid myopathy	24
Fluorescence guided fully endoscopic axillary dissection for locally advanced breast cancer. A feasible novel technique	24
Causes and consequences of delayed diagnosis in breast cancer screening; focus on mammographic features and tumour characteristics	24
Short-term surgical complications of skin-sparing mastectomy and direct-to-implant immediate breast reconstruction in women concurrently treated with adjuvant radiotherapy for breast cancer (2022; arc	24
Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge	24
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience	23
Breast cancer nutritional risk factors: insights from the Tesco 1.0 dataset	23
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomise	23
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	23
Breast cancer axillary dissection a “lost procedure, sometimes still necessary…” how to prevent the lost of a surgical technique using cadaver body and Simlife	22
A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305	22
How ‘breast aware’ are the Indian women? A study among the women visiting a tertiary-care, referral and teaching hospital	22
The value of palpation, US and NMR in staging of axilla in patients with breast cancer in order to avoid unnecessary ALND	22
The mediating effect of perceived injustice and pain catastrophizing in the relationship of pain on fatigue and sleep in breast cancer survivors: a cross-sectional study	22
Impact of musical training in breast cancer patients with post-treatment cognitive, funtional and emotional sequelae	22
Epigenetic silencing of P16INK4a hasten disease stage in Carcinoma of Breast: A hospital-based study of North India	22
Ultrahypofractionated radiation therapy for breast cancer: two-year normal tissue effects	22
MINIVAB trial: Minimally invasive breast cancer excision using vacuum assisted biopsy under ultrasound guidance	22
Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors	22
Cost-effectiveness of abemaciclib in early breast cancer patients: one size fits all or tailoring to patients’ needs	22
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	22
Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis	22
Accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with high-dose-rate brachytherapy (HDR)	22
Forty-eight weeks of yogic intervention improves serum interleukins IL-10 and IL-1β along with fatigue and quality of life during the radiotherapy/chemotherapy in breast cancer patients: a randomized	22
Clinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors	22
Impact of breast cancer diagnosis on women’s sexuality	22
Accelerated Partial Breast Irradiation With Multicatheter Brachytherapy after second conservative-surgery	22
Assessment and management of lesions of uncertain malignant potential of the breast at Trieste Breast Unit: a single center experience	21
Effect of glioma-derived immunoglobulin on biological function of glioma cells	21